AXGN

AxoGen, Inc. [AXGN] Stock Forecast

Q: What is AxoGen, Inc. stock symbol ?

AxoGen, Inc. is a US stock, located in Alachua of Fl and trading under the symbol AXGN

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AXGN Stock Summary

Earnings have grown 8.81% per last year.

Earnings are expected to rise 45.29% next year

EPS has been increasing for the past 3 quarters (Quarter statements)

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

AXGN has less than 1 year of cash runway

Top AXGN Correlated Resources

AXGN

Top 10 Correlated ETFs

AXGN

Top 10 Correlated Stocks

AXGN

In the News

07:00 29 Nov 2023 AXGN

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

09:46 29 Nov 2023 AXGN

AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

07:00 29 Nov 2023 AXGN

Axogen to Participate at Upcoming Investor Conferences

ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in two investor conferences in September.

09:34 29 Nov 2023 AXGN

AxoGen, Inc. (AXGN) Q2 2023 Earnings Call Transcript

AxoGen, Inc. (NASDAQ:AXGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Consultant Karen Zaderej - Chairman, Chief Executive Officer and President Pete Mariani - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Ross Osborn - Cantor Fitzgerald Caitlin Cronin - Canaccord Genuity Chris Pasquale - Nephron Research Operator Greetings. Welcome to the AxoGen, Inc. Reports Second Quarter 2023 Financial Results Conference Call.

06:54 29 Nov 2023 AXGN

AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates

AxoGen (AXGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.06 per share a year ago.

07:00 29 Nov 2023 AXGN

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2023 financial results on Monday, August 7, 2023 after the market closes. Axogen management will host an investment-community conference call and webcast at 4:30 p.m. ET following the release.

02:49 29 Nov 2023 AXGN

AxoGen: Far More Constructive With Q1 Numbers, Profitability The Next Hurdle

AxoGen is showing potential for growth, and management expects a record $160 million in revenue this year. Focus on core and active accounts has yielded positive results, with YoY growth of 23% and 9% respectively. However, the lack of earnings and catalysts makes it challenging to estimate an accurate valuation, warranting a hold rating for now.

10:57 29 Nov 2023 AXGN

Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet

The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

04:05 29 Nov 2023 AXGN

Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

04:00 29 Nov 2023 AXGN

Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023

ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

AXGN Financial details

Company Rating

Buy

Market Cap

256.11M

Income

-22.59M

Revenue

152.25M

Book val./share

2.27

Cash/share

0.76

Dividend

Dividend %

Employees

394

Optionable

Shortable

Yes

Earnings

07 Nov 2023

P/E

-11.85

Forward P/E

88.86

PEG

5.97

P/S

1.76

P/B

2.74

P/C

8.18

P/FCF

-11.13

Quick Ratio

2.1

Current Ratio

3.28

Debt / Equity

0.69

LT Debt / Equity

0.68

EPS (TTM)

-0.55

EPS next Y

0.07

EPS next Q

-0.01

EPS this Y

-4.41%

EPS next Y

-112.84%

EPS next 5Y

-96.33%

EPS last 5Y

1.61%

Revenue last 5Y

10.55%

Revenue Q/Q

8.17%

EPS Q/Q

-40.63%

SMA20

53.89%

SMA50

6.64%

SMA100

-31.8%

Inst Own

40.69%

Inst Trans

0.54%

ROA

-12%

ROE

-23%

ROC

-0.14%

Gross Margin

82%

Oper. Margin

-16%

Profit Margin

-15%

Payout

Shs Outstand

43.04M

Shs Float

32.29M

Target Price

52W Range

3.45-11.35

52W High

-43.45%

52W Low

+107.33%

RSI

72.64

Rel Volume

0.94

Avg Volume

442.14K

Volume

415.03K

Perf Week

7.24%

Perf Month

48.45%

Perf Quarter

-33.69%

Perf Half Y

-28.59%

Beta

0.794

Volatility

0.11%, 0.93%

Prev Close

4.01%

Price

6.22

Change

4.54%

AXGN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.26	2.72	2.81	3.09	3.29
Net income per share	-0.6	-0.74	-0.62	-0.68	-0.65
Operating cash flow per share	-0.48	-0.51	-0.24	-0.33	-0.38
Free cash flow per share	-0.66	-3.61	-0.81	-1.01	-0.89
Cash per share	3.14	2.46	2.6	2.04	1.16
Book value per share	3.96	3.37	3.08	2.73	2.4
Tangible book value per share	3.93	3.33	3.03	2.66	2.31
Share holders equity per share	3.96	3.37	3.08	2.73	2.4
Interest debt per share	0.03	0.09	1.37	1.67	1.62
Market cap	758.5M	701.91M	715.41M	386.18M	419.99M
Enterprise value	734.27M	669.52M	720.41M	420.88M	472.13M
P/E ratio	-33.87	-24.1	-28.84	-13.76	-15.36
Price to sales ratio	9.04	6.58	6.37	3.03	3.03
POCF ratio	-42.46	-35.32	-74.32	-28.81	-26.14
PFCF ratio	-31	-4.96	-22.2	-9.24	-11.25
P/B Ratio	5.16	5.31	5.81	3.43	4.16
PTB ratio	5.16	5.31	5.81	3.43	4.16
EV to sales	8.75	6.27	6.42	3.3	3.41
Enterprise value over EBITDA	-37.32	-25.54	-36.46	-20.09	-18.82
EV to operating cash flow	-41.11	-33.69	-74.84	-31.4	-29.39
EV to free cash flow	-30.01	-4.73	-22.36	-10.07	-12.65
Earnings yield	-0.03	-0.04	-0.03	-0.07	-0.07
Free cash flow yield	-0.03	-0.2	-0.05	-0.11	-0.09
Debt to equity	0	0.03	0.44	0.6	0.67
Debt to assets	0	0.02	0.27	0.32	0.35
Net debt to EBITDA	1.23	1.24	-0.25	-1.66	-2.08
Current ratio	11.57	6.47	6.36	5.23	4.13
Interest coverage	-16.97	-785.15	-21.99	-18.74	-47.61
Income quality	0.8	0.68	0.4	0.5	0.55
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.28	0.29	0.24	0.25	0.27
Research and developement to revenue	0.14	0.16	0.16	0.19	0.2
Intangibles to total assets	0.01	0.01	0.01	0.01	0.02
Capex to operating cash flow	0.37	6.12	2.35	2.12	1.32
Capex to revenue	-0.08	-1.14	-0.2	-0.22	-0.15
Capex to depreciation	-7.76	-42.28	-6.53	-5.99	-4.38
Stock based compensation to revenue	0.09	0.1	0.08	0.09	0.11
Graham number	7.33	7.5	6.56	6.47	5.92
ROIC	-0.14	-0.23	-0.12	-0.13	-0.15
Return on tangible assets	-0.14	-0.19	-0.12	-0.14	-0.14
Graham Net	3.26	2.39	1.13	0.26	-0.46
Working capital	137.91M	114.14M	122.42M	102.76M	74.32M
Tangible asset value	145.8M	130.64M	121.1M	109.69M	97.35M
Net current asset value	137.76M	112.53M	67.02M	31.58M	3.69M
Invested capital	0	0.03	0.44	0.6	0.67
Average receivables	13.19M	16.13M	17.28M	17.89M	20.17M
Average payables	3.88M	6.39M	6.43M	5.26M	7.44M
Average inventory	9.65M	12.92M	13.2M	14.61M	17.8M
Days sales outstanding	66.62	57.96	57.26	52.04	58.43
Days payables outstanding	127.58	173.82	77.75	94.28	135.5
Days of inventory on hand	338.42	291.62	211.9	265.71	285.76
Receivables turnover	5.48	6.3	6.37	7.01	6.25
Payables turnover	2.86	2.1	4.69	3.87	2.69
Inventory turnover	1.08	1.25	1.72	1.37	1.28
ROE	-0.15	-0.22	-0.2	-0.25	-0.27
Capex per share	-0.18	-3.1	-0.57	-0.69	-0.51

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.88	0.9	0.86	0.89	0.96
Net income per share	-0.09	-0.13	-0.16	-0.16	-0.1
Operating cash flow per share	-0.02	0.03	-0.17	0.01	0.04
Free cash flow per share	-0.12	-0.14	-0.28	-0.1	-0.05
Cash per share	1.26	1.22	0.89	0.81	0.76
Book value per share	2.4	2.53	2.29	2.27	2.27
Tangible book value per share	2.32	2.44	2.2	2.17	2.17
Share holders equity per share	2.4	2.53	2.29	2.27	2.27
Interest debt per share	1.6	1.69	1.58	1.57	1.59
Market cap	503.27M	398.87M	402.3M	391.33M	215.11M
Enterprise value	556.6M	451.01M	461.66M	435.44M	251.42M
P/E ratio	-34.35	-19.44	-14.99	-14.69	-13.15
Price to sales ratio	13.62	11.03	10.97	10.26	5.21
POCF ratio	-730.43	292.86	-54.2	1.34K	132.29
PFCF ratio	-96.14	-73.77	-33.58	-89.22	-94.35
P/B Ratio	4.96	3.95	4.13	4.03	2.2
PTB ratio	4.96	3.95	4.13	4.03	2.2
EV to sales	15.06	12.47	12.59	11.41	6.09
Enterprise value over EBITDA	-153	-98.67	-74.73	-71.02	-95.85
EV to operating cash flow	-807.84	331.14	-62.19	1.49K	154.62
EV to free cash flow	-106.32	-83.41	-38.54	-99.28	-110.27
Earnings yield	-0.01	-0.01	-0.02	-0.02	-0.02
Free cash flow yield	-0.01	-0.01	-0.03	-0.01	-0.01
Debt to equity	0.67	0.67	0.69	0.69	0.69
Debt to assets	0.35	0.35	0.35	0.35	0.35
Net debt to EBITDA	-14.66	-11.41	-9.61	-7.19	-13.84
Current ratio	4.35	4.13	4.18	3.6	3.28
Interest coverage	-79.59	140.2	-458.81	-46.64	-4.87
Income quality	0.16	-0.25	1.05	-0.04	-0.4
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.24	0.25	0.25	0.25	0.21
Research and developement to revenue	0.19	0.19	0.18	0.19	0.17
Intangibles to total assets	0.02	0.02	0.02	0.02	0.02
Capex to operating cash flow	6.6	-4.97	0.61	-16.02	-2.4
Capex to revenue	-0.12	-0.19	-0.12	-0.12	-0.09
Capex to depreciation	-3.57	-5.79	-3.66	-4.46	-2.77
Stock based compensation to revenue	0.1	0.11	0.08	0.14	0.12
Graham number	2.17	2.7	2.85	2.81	2.2
ROIC	-0.02	-0.03	-0.04	-0.04	-0.03
Return on tangible assets	-0.02	-0.03	-0.04	-0.04	-0.02
Graham Net	-0.36	-0.49	-0.65	-0.77	-0.82
Working capital	78.91M	74.32M	67.46M	62.24M	60.79M
Tangible asset value	98M	97.35M	93.66M	93.1M	93.52M
Net current asset value	8.38M	3.69M	-3.26M	-8.31M	-9.38M
Invested capital	0.67	0.67	0.69	0.69	0.69
Average receivables	20.87M	21.77M	22.23M	21.93M	22.42M
Average payables	0	4.48M	4.48M	0	0
Average inventory	19.17M	19.01M	19.38M	20.54M	22.13M
Days sales outstanding	52.02	55.21	54.69	50.89	50.73
Days payables outstanding	0	131.37	0	0	0
Days of inventory on hand	278.57	277.06	266.27	264.43	257.58
Receivables turnover	1.73	1.63	1.65	1.77	1.77
Payables turnover	0	0.69	0	0	0
Inventory turnover	0.32	0.32	0.34	0.34	0.35
ROE	-0.04	-0.05	-0.07	-0.07	-0.04
Capex per share	-0.11	-0.17	-0.11	-0.11	-0.09

AXGN Frequently Asked Questions

What is AxoGen, Inc. stock symbol ?

AxoGen, Inc. is a US stock , located in Alachua of Fl and trading under the symbol AXGN

What is AxoGen, Inc. stock quote today ?

AxoGen, Inc. stock price is $6.22 today.

Is AxoGen, Inc. stock public?

Yes, AxoGen, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 442.14K
Market Capitalization 256.11M
Employee 394
CEO Ms. Karen Zaderej
Headquarters Alachua,FL,US
IPO Date 1986-12-17
Website https://www.axogeninc.com

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.